ReviewHormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme2012
Cardiac cyclic nucleotide phosphodiesterases: function, regulation, and therapeutic prospects.
Review in Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 25 citations in OpenAlex.
- Phosphodiesterases Expression during Murine Cardiac Development.International journal of molecular sciences · 2021Article
- Rolipram, a PDE4 Inhibitor, Enhances the Inotropic Effect of Rat Heart by Activating SERCA2a.Frontiers in pharmacology · 2019Article
- Novel cilostamide analogs, phosphodiesterase 3 inhibitors, produce positive inotropic but differential lusitropic and chronotropic effects on isolated rat atria.Iranian journal of basic medical sciences · 2017Article
- Mechanisms of the cyclic nucleotide cross-talk signaling network in cardiac L-type calcium channel regulation.Journal of molecular and cellular cardiology · 2017Article
- Effects of Epinephrine on Inflammation-Related Gene Expressions in Cultured Rat Cardiomyocytes.Translational perioperative and pain medicine · 2017Article
- Rapid Screening of Potential Phosphodiesterase Inhibitors from the Roots ofEvidence-based complementary and alternative medicine : eCAM · 2017Article
- Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway.Journal of molecular and cellular cardiology · 2015Article
- Role of cAMP-phosphodiesterase 1C signaling in regulating growth factor receptor stability, vascular smooth muscle cell growth, migration, and neointimal hyperplasia.Circulation research · 2015Article
- cAMP and Ca²⁺ signaling in secretory epithelia: crosstalk and synergism.Cell calcium · 2014Review
- Therapeutic potential of PDE modulation in treating heart disease.Future medicinal chemistry · 2013Review
- Cyclic AMP, protein kinase A, and phosphodiesterases: proceedings of an international workshop.Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The second messengers cAMP and cGMP exist in multiple discrete compartments and regulate a variety of biological processes in the heart. The cyclic nucleotide phosphodiesterases, by catalyzing the hydrolysis of cAMP and cGMP, play crucial roles in controlling the amplitude, duration, and compartmentalization of cyclic nucleotide signaling. Over 60 phosphodiesterase isoforms, grouped into 11 families, have been discovered to date. In the heart, both cAMP- and cGMP-hydrolyzing phosphodiesterases play important roles in physiology and pathology. At least 7 of the 11 phosphodiesterase family members appear to be expressed in the myocardium, and evidence supports phosphodiesterase involvement in regulation of many processes important for normal cardiac function including pacemaking and contractility, as well as many pathological processes including remodeling and myocyte apoptosis. Pharmacological inhibitors for a number of phosphodiesterase families have also been used clinically or preclinically to treat several types of cardiovascular disease. In addition, phosphodiesterase inhibitors are also being considered for treatment of many forms of disease outside the cardiovascular system, raising the possibility of cardiovascular side effects of such agents. This review will discuss the roles of phosphodiesterases in the heart, in terms of expression patterns, regulation, and involvement in physiological and pathological functions. Additionally, the cardiac effects of various phosphodiesterase inhibitors, both potentially beneficial and detrimental, will be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.